| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.74% |
| NAV | ₹144.43 (22 Sep 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹5,791 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Bayer CropScience Ltd. | Healthcare | Equity | 4.2% |
| Emami Ltd. | FMCG | Equity | 3.8% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 3.4% |
| Mphasis Ltd. | Technology | Equity | 3.4% |
| Syngene International Ltd. | Healthcare | Equity | 2.9% |
| Atul Ltd. | Chemicals | Equity | 2.5% |
| Coromandel International Ltd. | Chemicals | Equity | 2.5% |
| Abbott India Ltd. | Healthcare | Equity | 2.4% |
| Multi Commodity Exchange India | Financial | Equity | 2.3% |
| Max Financial Services Ltd. | Financial | Equity | 2.2% |
L&T Midcap Fund Direct Growth is a Equity Mutual Fund Scheme launched by L&T Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Soumendra Nath Lahiri, Vihang Naik is the Current Fund Manager of L&T Midcap Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹5,791 Cr and the Latest NAV as of 22 Sep 2020 is ₹144.43.
The L&T Midcap Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year.
To generate capital appreciation by investing primarily in midcap stocks. The Scheme will invest primarily in companies whose market capitalization falls between the highest and the lowest constituent of the Nifty Free Float Midcap 100 Index.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.